MRC Adjuvant Gastric Infusional Chemotherapy Trial

Conditions

Gastrointestinal cancer Cancer Gastrointestinal cancer

Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell et al. (17 authors)

Frontiers in Oncology2023-11-293 citations

10.3389/fonc.2023.1258365

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants.

2006-07-014,419 citations

10.1056/nejmoa055531

Interventions

Three cycles of pre- and post-operative ECF (Epirubicin, Cisplatin and 5-Fluorouracil) chemotherapy versus surgery alone. Follow-up: all patients will be followed 6 monthly to 2 years

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically proven adenocarcinoma (Stage II or greater) of the lower third oesophagus or stomach, that is considered to be non-urgently resectable with no evidence of distant metastasis 2. Suitable and fit for cytotoxic chemotherapy 3. WHO performance status of 0 or 1

Exclusion criteria

Exclusion criteria: 1. Other malignant disease other than non-melanomatous skin cancer or in situ carcinoma of the cervix; 2. previous cytotoxic chemotherapy or radiotherapy

Design outcomes

Primary

Measure	Time frame
1. Survival time 2. Disease-free survival 3. Quality of life 4. Tumour response	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

England, United Kingdom

Outcome results

None listed